Global Calcitonin Injection Market Size By Type (Elcatonin Injection, Salmon Calcitonin Injection), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Calcitonin Injection Market was valued at USD 3.2 billion in 2023 and is projected to reach USD 5.6 billion by 2031, growing at a CAGR of 7.4% during the forecast period from 2023 to 2031. Calcitonin injections are primarily used in the treatment of osteoporosis, Paget's disease, and hypercalcemia. The increasing geriatric population, rising incidence of osteoporosis, and heightened awareness regarding bone health are fueling the demand for calcitonin injections. Additionally, continuous improvements in drug formulation and delivery techniques are expanding the adoption of calcitonin-based therapies.

Drivers:

1. Rising Prevalence of Osteoporosis:

The increasing global burden of osteoporosis, especially among postmenopausal women and the elderly, is a key growth driver. Calcitonin injections offer an effective therapeutic approach for bone density loss, reducing fracture risk and improving patient outcomes.

2. Expanding Geriatric Population:

Aging demographics globally are associated with a higher incidence of bone-related disorders, driving the demand for calcitonin therapies. The elderly population is more susceptible to fractures and calcium imbalance, reinforcing the market need.

3. Advancements in Drug Formulation and Administration:

Innovations in calcitonin drug formulations, such as synthetic salmon calcitonin with improved bioavailability and patient tolerability, are bolstering market growth. Enhanced delivery systems (e.g., prefilled syringes) are increasing patient compliance.

Restraints:

1. Availability of Alternative Therapies:

Bisphosphonates and newer biologics offer competitive treatment options for osteoporosis, limiting the uptake of calcitonin injections.

2. Regulatory and Safety Concerns:

Certain studies linking long-term calcitonin use to increased cancer risk have led to regulatory scrutiny in some markets, impacting prescription rates.

Opportunity:

1. Rising Demand in Emerging Economies:

Developing countries are witnessing increased healthcare spending and better access to osteoporosis diagnosis and treatment. This trend opens avenues for market expansion, especially with cost-effective generic calcitonin solutions.

2. Growing Awareness Campaigns on Bone Health:

Public health initiatives and awareness programs by governments and NGOs are encouraging bone health screenings and early treatment, indirectly benefiting the calcitonin injection market.

Market by System Type Insights:

The Synthetic Salmon Calcitonin segment led the market in 2023, credited to its high potency and favorable efficacy profile compared to human calcitonin. It continues to dominate due to its proven clinical benefits and extended history of use in osteoporosis treatment protocols.

Market by End-use Insights:

Hospitals emerged as the largest end-use segment in 2023, holding over 55% of the global market share. Hospitals are the primary administration centers for calcitonin injections, especially for treating acute cases of hypercalcemia and Paget’s disease. Meanwhile, homecare settings are expected to gain momentum owing to the availability of self-administrable formulations and rising patient preference for convenient treatment options.

Market by Regional Insights:

North America held the largest share of the global calcitonin injection market in 2023, driven by a high prevalence of osteoporosis, favorable reimbursement policies, and the presence of key market players. Asia-Pacific is anticipated to witness the highest growth rate over the forecast period, supported by rapid urbanization, aging populations, and expanding healthcare infrastructure in countries like China and India.

Competitive Scenario:

Key players operating in the Global Calcitonin Injection Market include Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceuticals, F. Hoffmann-La Roche Ltd., Mylan N.V., Cipla Inc., and Hikma Pharmaceuticals PLC. These companies are focusing on geographic expansion, cost-effective formulations, and regulatory approvals to enhance their market share.

Key Market Developments:

2023: Teva Pharmaceuticals launched a biosimilar version of salmon calcitonin injection in select Latin American markets, offering a more affordable option for osteoporosis management.

2024: Novartis AG received expanded approval for its calcitonin injection in Southeast Asia, targeting the growing geriatric population in the region.

2025: Cipla Inc. collaborated with a leading diagnostics firm to provide bundled osteoporosis screening and treatment packages in urban India.

Scope of Work – Global Calcitonin Injection Market

FAQs:

1) What is the current market size of the Global Calcitonin Injection Market?

The market size was valued at USD 3.2 billion in 2023.

2) What is the major growth driver of the Global Calcitonin Injection Market?

The major growth driver is the rising prevalence of osteoporosis and an aging population requiring bone health treatments.

3) Which is the largest region during the forecast period in the Global Calcitonin Injection Market?

North America is projected to remain the largest region due to advanced healthcare infrastructure and high awareness.

4) Which segment accounted for the largest market share in the Global Calcitonin Injection Market?

The Synthetic Salmon Calcitonin segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Calcitonin Injection Market?

Key players include Novartis AG, Pfizer Inc., Teva Pharmaceuticals, GlaxoSmithKline plc, and Cipla Inc.